AbbVie presents long-term RINVOQ vitiligo data
AbbVie presented long-term data on RINVOQ (upadacitinib) showing continued repigmentation in non-segmental vitiligo.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.